Pierre Fab­ry forges I/O dis­cov­ery pact; Ac­tini­um surges on CHMP sup­port

→ France’s Pierre Fab­re struck a deal with H-Im­mune SAS to de­vel­op new im­munother­a­pies, uti­liz­ing H-Im­mune’s tech­nol­o­gy plat­form to gen­er­ate lead can­di­dates of ful­ly hu­man an­ti­bod­ies to serve as the ini­tial step in a pro­gram to de­vel­op im­muno-on­col­o­gy ther­a­peu­tics. “This trans­ac­tion strength­ens Pierre Fab­re’s po­si­tion in the ar­eas of im­muno-on­col­o­gy and nov­el cut­ting-edge bio­ther­a­peu­tics,” said Lau­rent Au­doly, head of R&D of Pierre Fab­re Phar­ma­ceu­ti­cals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER